Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

Launched by GLAXOSMITHKLINE · Oct 6, 2006

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy male or female adults aged between 19 to 64 years, inclusive for the primary cohort), or aged 65 years or older (for the exploratory cohort), at the time of vaccination.
• Exclusion Criteria:
• • Administration of an influenza vaccine within six months prior to study entry
• • Administration of a diphtheria-tetanus (Td) booster within the previous 5 years.
• • Administration of a Tdap vaccine at any time prior to study entry.
• • Administration of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding vaccination, or planned use during the entire study period.
• • History of diphtheria and/or tetanus and/or pertussis disease.
• • History of serious allergic reaction (e.g. anaphylaxis) following any other tetanus toxoid, diphtheria toxoid or pertussis-containing vaccine or influenza vaccine or any component of the study vaccines.